Orgenesis Inc. has commenced activities under its joint venture agreement with Atvio Biotech Ltd. Under the terms of the joint venture (JV), Atvio is responsible for providing contract development and manufacturing services and supporting the global expansion of MaSTherCell, a wholly-owned subsidiary of Orgenesis. The parties are pursuing the JV through Atvio, in which Orgenesis holds a 50% participating interest, with the remaining 50% participating interest being held by the other shareholders of Atvio. Under the JV, Orgenesis will integrate Atvio's operations into its global contract manufacturing strategy in the field of cell therapy manufacturing.

Atvio has announced the appointment of Dr. Ohad Karnieli as CEO of the JV. Dr. Karnieli is a highly experienced professional in the area of cell therapy manufacturing. Dr. Karnieli has expanded his experience as the CEO &Co-founder of Karnieli Ltd. following his position as the VP of Technology and Manufacturing at Pluristem Therapeutics Inc. Dr. Karnieli currently serves as the Chairman of the process and product development committee of the International Society for Cell Therapy.